文献速递神经免疫神经肌肉病

纹状体抗体在副肿瘤及重症肌无力副肿瘤检测中的临床价值

Clinical Utility of Striational Antibodies in Paraneoplastic and Myasthenia Gravis Paraneoplastic Panels.
PubMed 文献 · Neurology · 2021-06-14

该研究回顾性分析了2012至2018年梅奥诊所38,502例副肿瘤评估和1,899例重症肌无力(MG)患者的纹状体抗体(StrAbs)检测数据。结果显示,尽管StrAbs与癌症存在统计学关联,但其诊断准确性低(副肿瘤组AUC 0.505),且与神经表型无关;在MG组中对胸腺癌的准确性也较差(AUC 0.634)。结论认为StrAbs不应作为副肿瘤或MG评估的常规项目。

要点

  • StrAbs在副肿瘤评估中癌症阳性率仅5% vs 4%,AUC 0.505,无诊断准确性。
  • MG患者中StrAbs对胸腺癌AUC 0.634,推荐 cutoff 1:60,灵敏度56%、特异度71%。
  • StrAbs阳性未改善癌症预测,且导致CT过度使用,建议从检测面板中移除。

核心结论

  • StrAbs与癌症虽存在统计学关联,但不具备预测恶性肿瘤或神经表型的敏感性和特异性。
  • 将StrAbs从副肿瘤或MG评估中移除可改善现有MG检测的诊断特性。

研究设计与样本

  • 回顾性队列研究,基于梅奥诊所统一数据平台,纳入2012年1月1日至2018年12月31日期间检测StrAbs的患者。
  • 共分析38,502例副肿瘤评估和1,899例MG患者,评估神经诊断和癌症情况。

主要发现

  • 副肿瘤评估中,StrAbs阳性率癌症组5%(321/6,775) vs 无癌症组4%(1,154/31,727),p<0.0001,OR 1.35(CI 1.19-1.53),AUC 0.505。
  • 副肿瘤组中无神经表型与StrAbs显著相关;MG癌症患者StrAbs阳性率高于副肿瘤癌症患者(p<0.0001)。
  • MG评估中,StrAbs阳性率癌症组46%(217/474) vs 无癌症组26%(372/1,425),p<0.0001,OR 2.39(CI 1.9-2.96)。
  • MG组中对胸腺癌的AUC 0.634(推荐 cutoff 1:60,灵敏度56%,特异度71%),对胸外癌AUC 0.543。
  • 副肿瘤或MG评估中,抗体阳性值未改善癌症预测;StrAbs阳性者更易接受CT检查(p=0.0001),癌症发现率3%(12/468)。

关键数值与推荐

  • StrAbs对副肿瘤癌症诊断AUC 0.505,无诊断准确性。
  • StrAbs对MG相关胸腺癌推荐 cutoff 1:60,灵敏度56%、特异度71%,AUC 0.634。
  • StrAbs对MG相关胸外癌AUC 0.543,准确性更差。

临床怎么用

  • 不应将StrAbs作为副肿瘤或MG评估的常规筛查项目。
  • StrAbs阳性结果不应单独驱动CT等影像学检查,避免过度 utilization。
  • 临床怀疑副肿瘤或MG时,应依赖更具特异性和敏感性的抗体组合及临床评估。

局限性

  • 回顾性研究设计,可能存在选择偏倚和信息偏倚。
  • 单中心(梅奥诊所)数据,外推性需谨慎。
  • 未报告其他潜在混杂因素的控制情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To critically assess the clinical utility of striational antibodies (StrAbs) within paraneoplastic and myasthenia gravis (MG) serologic evaluations. METHODS: All Mayo Clinic patients tested for StrAbs from January 1, 2012, to December 31, 2018, utilizing Mayo's Unified Data Platform (UDP) were reviewed for neurologic diagnosis and cancer. RESULTS: A total of 38,502 unique paraneoplastic evaluations and 1,899 patients with MG were tested. In paraneoplastic evaluations, the StrAbs positivity rate was higher in cancer vs without cancer (5% [321/6,775] vs 4% [1,154/31,727]; p < 0.0001; odds ratio [OR] 1.35; confidence interval [CI] 1.19-1.53), but receiver operating characteristic (ROC) analysis indicated no diagnostic accuracy in cancer (area under the ROC curve [AUC] 0.505). No neurologic phenotype was significantly associated with StrAbs in the paraneoplastic group. Positivity was more common in all MG cancers compared to paraneoplastic cancers (p < 0.0001). In MG evaluations, the StrAbs positivity rate was higher in those with cancer vs without (46% [217/474] vs 26% [372/1,425]; p < 0.0001; OR 2.39, CI 1.9-2.96), with ROC analysis indicating poor diagnostic accuracy for thymic cancer (AUC 0.634, recommended cutoff = 1:60, sensitivity = 56%, specificity = 71%), with worse accuracy for extrathymic cancers (AUC 0.543). In paraneoplastic or MG evaluations, the value of antibody positivity did not improve cancer predictions. Paraneoplastic evaluated patients with positive StrAbs were more likely to obtain CT (p = 0.0001), with cancer found in 3% (12/468). CONCLUSION: Despite a statistically significant association with cancer, an expansive review of performance in clinical service demonstrates that StrAbs are neither specific nor sensitive in predicting malignancy or neurologic phenotypes. CT imaging is overutilized with positive StrAbs results. Removal of StrAbs from paraneoplastic or MG evaluations will improve the diagnostic characteristics of the current MG test. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that the presence of StrAbs does not accurately identify patients with malignancy or neurologic phenotypes.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Shelly S, Mills JR, Dubey D, et al. Clinical Utility of Striational Antibodies in Paraneoplastic and Myasthenia Gravis Paraneoplastic Panels. Neurology. 2021. PMID: 33903199. doi:10.1212/WNL.0000000000012050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。